CymaBay Therapeutics, Inc. CBAY
Day range unavailable
52-week range unavailable
- Market cap
- 3.73B
- Revenue (ttm)
- 31.07M
- Shares out
- 114.78M
- Forward P/E
- -30.93
- Beta
- 0.32
- Analysts
- Hold
- Price target
- 32.50 (+0.1%)
- Earnings date
- Feb 28, 2024
2Y +29.33 (+931.11%)
Key statistics
- Enterprise value
- 3.45B
- PEG ratio
- 0.00
- Price / sales
- 119.98
- Price / book
- 12.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -54.82M
- Total cash
- 394.26M
- Total debt
- 114.49M
- Return on equity
- -64.17%
- Short % of float
- 5.88%
- 50-day average
- 29.11
- 200-day average
- 19.07
Analyst view
Consensus: hold
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 28, 2024
Expected Feb 28, 2024. Consensus EPS estimate -0.30.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 28, 2024 | Dec 1, 2023 | -0.32 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -0.30 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.21 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.16 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | -0.30 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.30 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 2023 | UBS | main | Buy | Buy |
| Sep 7, 2023 | B. Riley Securities | main | Buy | Buy |
| Sep 7, 2023 | BTIG | main | Buy | Buy |
| Sep 7, 2023 | Raymond James | main | Strong Buy | Strong Buy |
| Sep 6, 2023 | Raymond James | main | Strong Buy | Strong Buy |
| Sep 6, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cymabay.com
News
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B 
Earnings Scheduled For November 7, 2023 - Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday
Earnings Scheduled For August 10, 2023 - Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday 
Earnings Scheduled For May 15, 2023 - Earnings Scheduled For March 16, 2023
Earnings Scheduled For November 14, 2022 - Earnings Scheduled For August 11, 2022
Your note
Sign in to keep a note on CBAY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DICKINSON-EASON KLARA A | Officer | Stock Award(Grant) | Jan 23, 2024 | 21,000 |
| DORLING JANET | Director | Sale | Feb 11, 2024 | 0 |
| EMSTER KURT VON | Director | Sale | Sep 28, 2023 | 108,406 |
| GOLDFISCHER CARL S | Director | Sale | Feb 6, 2019 | 0 |
| KIM DENNIS D | Officer | Sale | Apr 16, 2023 | 20,000 |
| MCWHERTER CHARLES A | Officer | Stock Award(Grant) | Jan 23, 2024 | 46,938 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.33% | 10,300,000 | 112.78M | Jun 29, 2023 |
| Janus Henderson Group PLC | 7.02% | 7,746,587 | 84.83M | Jun 29, 2023 |
| Blackrock Inc. | 6.80% | 7,504,670 | 82.18M | Jun 29, 2023 |
| Vanguard Group Inc | 4.67% | 5,148,880 | 56.38M | Jun 29, 2023 |
| Octagon Capital Advisors LP | 4.14% | 4,570,918 | 50.05M | Jun 29, 2023 |
| Adage Capital Partners GP L.L.C. | 3.99% | 4,401,292 | 48.19M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.71% | 2,986,738 | 32.70M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 2.03% | 2,235,209 | 30.73M | Aug 30, 2023 |
| Janus Henderson Global Life Sciences Fund | 1.51% | 1,663,467 | 18.21M | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.13% | 1,252,335 | 13.71M | Jun 29, 2023 |
| Janus Henderson Triton Fund | 1.08% | 1,193,958 | 13.07M | Jun 29, 2023 |
| PGIM Jennison Health Sciences Fd | 1.02% | 1,122,754 | 15.44M | Aug 30, 2023 |